参仙升脉口服液治疗缓慢性心律失常的研究进展

Research progress in Shenxian Shengmai oral liquid in treating bradycardia

参仙升脉(SXSM)口服液是一种具有明显疗效和安全性的中成药。在现代药理学研究的基础上,各种动物和细胞研究的积累证据表明,SXSM可通过增加细胞内环磷酸腺苷的浓度、促进钙通道的开放、改善病窦综合征患者窦房结病理破坏程度、延缓窦房结细胞纤维化进程、增加I f电流和调节基因表达等机制加快心率,改善缓慢性心律失常患者的临床症状。大量临床研究表明,SXSM对比传统提高心率的中成药和西药,对心率的提高具有更好的疗效。

Shenxian Shengmai(SXSM)oral liquid is a Chinese patent medicine with proven curative efficacy and safety.Evidence from modern pharmacological studies with various animals and cells show that SXSM can accelerate the heart rate and improve the clinical symptoms of patients with bradycardia by increasing the concentration of cyclic adenosine monophosphate in cells,promoting the opening of calcium channels,improving the degree of pathological damage,delaying fibrosis of sinus node in patients with sick sinus syndrome,increasing I f current and regulating gene expression.A large number of clinical studies have shown that SXSM has a better efficacy on heart rate improvement than other traditional Chinese patent medicines and western medicines that increase heart rate.